Third ERTS Symposium: Abstracts

Abstracts are provided for the 112 papers presented at the Earth Resources Program Symposium held at Washington, D.C., 10-14 December, 1973

Relatively hyperbolic groups

In this paper we develop some of the foundations of the theory of relatively hyperbolic groups as originally formulated by Gromov. We prove the equivalence of two definitions of this notion. One is essentially that of a group admitting a properly discontinuous geometrically finite action on a proper hyperbolic space, that is, such that every limit point is either a conical limit point or a bounded parabolic point. The other is that of a group which admits a cofinite action on a connected fine hyperbolic graph. We define a graph to be "fine" if there are only finitely many circuits a given length containing any given edge, and we develop some of the properties of this notion. We show how a relatively hyperbolic group can be assumed to act on a proper hyperbolic space of a particular geometric form. We define the boundary of a relatively hyperbolic group, and show that the limit set of any geometrically finite action of the group is equivariantly homeomorphic to this boundary. This generalizes a result of Tukia for geometrically finite kleinian groups. We also describe when the boundary is connected. © 2012 World Scientific Publishing Compan

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

This phase 2 study evaluated the safety and efficacy of alemtuzumab in 22 patients with advanced mycosis fungoides/Sezary syndrome (MF/SS). Most patients had stage III or IV disease, reduced performance status, and severe itching. The overall response (OR) rate was 55%, with 32% of patients in complete remission (CR) and M in, partial remission (PR). Sezary cells were cleared from the blood in 6 of 7 (86%) patients, and CR in lymph nodes was observed in 6 of 11 (55%) patients. The effect was better on erythro-derma (OR, 69%) than on plaque or skin tumors (OR, 40%) and in patients who had received 1 to 2 previous regimens (OR, 80%) thin in those who had received 3 or more prior regimens (OR, 33%). Itching, self-assessed on a 0 to 10 visual analog scale, was reduced from a median of 8 before treatment to 2 at end. of therapy. Median time to treatment failure was 12 months (range, 5-32+ months). Cytomegalovirus (CMV), reactivation (causing fever without pneumonitis and responding to ganciclovir) occurred in 4 (18%) patients. Six additional patients had suspect or manifest infection (fever of unknown origin, 3; generalized herpes simplex, 1; fatal aspergillosis, 1). One patient had fatal Mycobacterium pneumonia at 10+ months. All serious infectious adverse events (except CMV) occurred in patients who had received 3 or more prior regimens. Progression of squamous cell skin carcinoma was noted in 1 patient. Alemtuzumab shows promising clinical activity and an acceptable safety profile in patients with advanced MF/SS, particularly in patients with erythroderma and severe itching and those who were not heavily pretreated. (C) 2003 by The American Society of Hematology